公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

Applicant: ABL Bio Inc.

Inventor： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

公开(公告)号：US12049493B2

公开(公告)日：2024-07-30

申请号：US16475853

申请日：2018-01-05

Applicant: ABL Bio Inc.

Inventor： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Seung-Jae Lee ,  Tae Kyung Kim ,  Min Sun Choi ,  Weonkyoo You ,  Jaeho Jung ,  Juhee Kim ,  Jinwon Jung ,  Yeunju Kim ,  Yonggyu Son ,  Byungje Sung

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/14 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61P25/14 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N2800/2835

Abstract: The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

公开(公告)号：US20210024638A1

公开(公告)日：2021-01-28

申请号：US16939472

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US12195537B2

公开(公告)日：2025-01-14

申请号：US17296752

申请日：2019-12-02

Applicant: ABL Bio Inc.

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Hyejin Chung ,  Uijung Jung ,  Youngdon Pak ,  Jun Hyun Jeong ,  Yeunju Kim ,  Seawon Ahn ,  Byungje Sung

IPC: G01N31/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46 ,  G01N33/53

Abstract: Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

公开(公告)号：US12168690B2

公开(公告)日：2024-12-17

申请号：US16939472

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US12252541B2

公开(公告)日：2025-03-18

申请号：US17053256

申请日：2019-06-26

Applicant: ABL BIO INC.

Inventor： Kyungjin Park ,  Hyejin Chung ,  Kyeongsu Park ,  Yangsoon Lee ,  Mikyung Chang ,  Jaehyoung Jeon ,  Youngkwang Kim ,  Junhyun Jeong ,  Jiseon Yoo ,  Yeunju Kim ,  Donghoon Yeom ,  Eunjung Kim ,  Bora Lee ,  Jinwon Jung

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/705

Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

公开(公告)号：US12122830B1

公开(公告)日：2024-10-22

申请号：US17057646

申请日：2019-05-23

Applicant: ABL Bio Inc.

Inventor： Yangsoon Lee ,  Juhee Kim ,  Kyungjin Park ,  Donghoon Yeom ,  Kyeongsu Park ,  Hyejin Chung ,  Yeunju Kim ,  Eunyoung Park ,  Ui-Jung Jung ,  Eunsil Sung ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  G01N2333/705 ,  G01N2333/912

Abstract: The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

公开(公告)号：US11891445B1

公开(公告)日：2024-02-06

申请号：US17057643

申请日：2019-05-24

Applicant: ABL Bio Inc.

Inventor： Kyeongsu Park ,  Yangsoon Lee ,  Hyejin Chung ,  Uijung Jung ,  Yong-Gyu Son ,  Sang-Jun Ha ,  Myeong Joon Kim ,  Eunyoung Park ,  Kyungjin Park ,  Eunsil Sung ,  Yeunju Kim ,  Jinhyung Ahn ,  Byungje Sung ,  Daehae Song ,  Youngdon Pak

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.